197 related articles for article (PubMed ID: 24786232)
1. SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models.
Yan PK; Zhang LN; Feng Y; Qu H; Qin L; Zhang LS; Leng Y
Acta Pharmacol Sin; 2014 May; 35(5):613-24. PubMed ID: 24786232
[TBL] [Abstract][Full Text] [Related]
2. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity.
Yamamoto K; Uchida S; Kitano K; Fukuhara N; Okumura-Kitajima L; Gunji E; Kozakai A; Tomoike H; Kojima N; Asami J; Toyoda H; Arai M; Takahashi T; Takahashi K
Br J Pharmacol; 2011 Sep; 164(1):181-91. PubMed ID: 21410690
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the effect of canagliflozin on renal glucose reabsorption and progression of hyperglycemia in zucker diabetic Fatty rats.
Kuriyama C; Xu JZ; Lee SP; Qi J; Kimata H; Kakimoto T; Nakayama K; Watanabe Y; Taniuchi N; Hikida K; Matsushita Y; Arakawa K; Saito A; Ueta K; Shiotani M
J Pharmacol Exp Ther; 2014 Nov; 351(2):423-31. PubMed ID: 25216746
[TBL] [Abstract][Full Text] [Related]
4. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.
Fujimori Y; Katsuno K; Nakashima I; Ishikawa-Takemura Y; Fujikura H; Isaji M
J Pharmacol Exp Ther; 2008 Oct; 327(1):268-76. PubMed ID: 18583547
[TBL] [Abstract][Full Text] [Related]
5. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.
Liang Y; Arakawa K; Ueta K; Matsushita Y; Kuriyama C; Martin T; Du F; Liu Y; Xu J; Conway B; Conway J; Polidori D; Ways K; Demarest K
PLoS One; 2012; 7(2):e30555. PubMed ID: 22355316
[TBL] [Abstract][Full Text] [Related]
6. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.
Suzuki M; Honda K; Fukazawa M; Ozawa K; Hagita H; Kawai T; Takeda M; Yata T; Kawai M; Fukuzawa T; Kobayashi T; Sato T; Kawabe Y; Ikeda S
J Pharmacol Exp Ther; 2012 Jun; 341(3):692-701. PubMed ID: 22410641
[TBL] [Abstract][Full Text] [Related]
7. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.
Nagata T; Fukuzawa T; Takeda M; Fukazawa M; Mori T; Nihei T; Honda K; Suzuki Y; Kawabe Y
Br J Pharmacol; 2013 Oct; 170(3):519-31. PubMed ID: 23751087
[TBL] [Abstract][Full Text] [Related]
8. EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone rats.
Zhang W; Welihinda A; Mechanic J; Ding H; Zhu L; Lu Y; Deng Z; Sheng Z; Lv B; Chen Y; Roberge JY; Seed B; Wang YX
Pharmacol Res; 2011 Apr; 63(4):284-93. PubMed ID: 21215314
[TBL] [Abstract][Full Text] [Related]
9. Swertisin, a novel SGLT2 inhibitor, with improved glucose homeostasis for effective diabetes therapy.
Bhardwaj G; Vakani M; Srivastava A; Patel D; Pappachan A; Murumkar P; Shah H; Shah R; Gupta S
Arch Biochem Biophys; 2021 Oct; 710():108995. PubMed ID: 34289381
[TBL] [Abstract][Full Text] [Related]
10. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
[TBL] [Abstract][Full Text] [Related]
11. KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models.
Shibazaki T; Tomae M; Ishikawa-Takemura Y; Fushimi N; Itoh F; Yamada M; Isaji M
J Pharmacol Exp Ther; 2012 Aug; 342(2):288-96. PubMed ID: 22537769
[TBL] [Abstract][Full Text] [Related]
12. Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
Arch Pharm Res; 2016 Feb; 39(2):259-270. PubMed ID: 26450351
[TBL] [Abstract][Full Text] [Related]
13. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
Katsuno K; Fujimori Y; Takemura Y; Hiratochi M; Itoh F; Komatsu Y; Fujikura H; Isaji M
J Pharmacol Exp Ther; 2007 Jan; 320(1):323-30. PubMed ID: 17050778
[TBL] [Abstract][Full Text] [Related]
14. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
[TBL] [Abstract][Full Text] [Related]
15. Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents.
Oguma T; Nakayama K; Kuriyama C; Matsushita Y; Yoshida K; Hikida K; Obokata N; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Shiotani M
J Pharmacol Exp Ther; 2015 Sep; 354(3):279-89. PubMed ID: 26105952
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Qun L; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
Naunyn Schmiedebergs Arch Pharmacol; 2012 Apr; 385(4):423-36. PubMed ID: 22139434
[TBL] [Abstract][Full Text] [Related]
17. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function.
Jurczak MJ; Lee HY; Birkenfeld AL; Jornayvaz FR; Frederick DW; Pongratz RL; Zhao X; Moeckel GW; Samuel VT; Whaley JM; Shulman GI; Kibbey RG
Diabetes; 2011 Mar; 60(3):890-8. PubMed ID: 21357472
[TBL] [Abstract][Full Text] [Related]
18. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Qun L; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
J Pharmacol Sci; 2012; 120(1):36-44. PubMed ID: 22971845
[TBL] [Abstract][Full Text] [Related]
19. [Role of the kidneys in glucose homeostasis. Implication of sodium-glucose cotransporter 2 (SGLT2) in diabetes mellitus treatment].
Girard J
Nephrol Ther; 2017 Apr; 13 Suppl 1():S35-S41. PubMed ID: 28577741
[TBL] [Abstract][Full Text] [Related]
20. SGLT2 knockout prevents hyperglycemia and is associated with reduced pancreatic β-cell death in genetically obese mice.
Jurczak MJ; Saini S; Ioja S; Costa DK; Udeh N; Zhao X; Whaley JM; Kibbey RG
Islets; 2018; 10(5):181-189. PubMed ID: 30118626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]